SAN DIEGO--(BUSINESS WIRE)--April 11, 2006--Aethlon Medical, Inc. (OTCBB:AEMD - News), a pioneer in developing therapeutic devices for infectious disease, announced today that it has submitted a cancer research grant application entitled “Tumor Exosome Removal to Stimulate Cancer-Specific Immunity.” The grant was submitted to the National Institute of Health (NIH) and directed to the National Cancer Institute as a Phase I Small Business Innovation Grant. A review and formal response to the grant application is expected from the NIH in August. The grant application discusses the potential use of the Aethlon Hemopurifier(TM )as a method to remove exosomes that suppress the immune response in cancer patients. Significant levels of immune-suppressive exosomes are identified in cancer patients, whereas healthy individuals maintain negligible levels. Aethlon proposes to improve the immune response to malignancies by reducing the presence of tumor-derived exosomes, thereby activating immunity to cancers. There is no assurance that Aethlon will derive grant income related to this research initiative.
